BRCA1 and non-small cell lung carcinoma: Univariate analysis of NSCLC also showed that patients with BRCA1/2 mutation had a higher ORR [60% (95%CI, 31.9–88.1%) vs. 0% (95%CI, 0–36.9%), P = 0.035], and patients with baseline lymphocyte ≥0.8 × 109/l had a better mPFS [8.7 m (95%CI, 0–20.9) vs. 2.0 m (0.1–3.8), P = 0.021).